文献速递产科母胎医学

持续性无解释或失败的产前游离DNA筛查提示高危妊娠并与干扰cfDNA分析的生物学因素相关:一项前瞻性队列研究

Persistent Uninterpretable or Failed Prenatal Cell-Free DNA Screening Indicates a High-Risk Pregnancy and is Associated With Biological Factors Interfering With cfDNA-Analysis: A Prospective Cohort Study.
PubMed 文献 · Prenat Diagn · 2025-03-20

该前瞻性队列研究纳入2020年12月至2022年12月持续性无解释产前cfDNA筛查的孕妇,68%因低胎儿分数(LFF)、32%因低质量评分(LQS)。肥胖和自身免疫病显著过代表,24周第三次cfDNA筛查在77.1%病例中可解释,LFF组成功率87.8%。不良围产结局见于69.9%患者,LFF组更高;作者认为可考虑母体自身免疫筛查,第三次cfDNA筛查有助于分层真正高危妊娠。

要点

  • 持续性无解释cfDNA筛查中68%为LFF、32%为LQS,肥胖和自身免疫病显著过代表。
  • 24周第三次cfDNA筛查总体可解释率77.1%,LFF组成功率87.8%。
  • 不良围产结局见于69.9%患者,LFF组不良围产结局率更高。

核心结论

  • 持续性无解释产前cfDNA筛查提示不良围产结局风险较高,尤其在LFF病例中。
  • 作者认为可考虑母体自身免疫筛查以识别高危妊娠。
  • 作者认为妊娠后期第三次cfDNA筛查有助于分层真正高危妊娠,并使初始无解释结果的患者能对诊断性检测做出知情决策。

研究设计与样本

  • 前瞻性队列研究,纳入2020年12月至2022年12月持续性无解释产前cfDNA筛查的孕妇。
  • cfDNA筛查结果因低质量评分(LQS)或低胎儿分数(LFF)归类为无解释。
  • 妊娠后期进行母体自身免疫筛查和第三次产前cfDNA筛查,分析母体特征和围产结局数据。

主要发现

  • 123例产前cfDNA筛查失败的孕妇中,68%归因于LFF,32%归因于LQS。
  • 肥胖和自身免疫病显著过代表。
  • 24周第三次产前cfDNA筛查在77.1%病例中可解释,LFF组成功率更高(87.8%)。
  • 母体自身免疫筛查显示2.4%病例抗磷脂抗体三项阳性且未知。
  • 69.9%患者记录到不良围产结局,LFF组不良围产结局率更高。

临床怎么用

  • 作者认为可考虑母体自身免疫筛查以识别高危妊娠。
  • 作者认为妊娠后期第三次cfDNA筛查有助于分层真正高危妊娠,并使初始无解释结果的患者能对诊断性检测做出知情决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate maternal characteristics, underlying factors and perinatal outcome in pregnancies with persistent uninterpretable prenatal cfDNA screening in a general obstetric population (GOP). METHODS: This study included pregnant individuals with persistent uninterpretable prenatal cfDNA screening results from December 2020 to December 2022. Prenatal cfDNA screening results were classified as uninterpretable due to low quality score (LQS) or low fetal fraction (LFF). Maternal autoimmune screening and a third prenatal cfDNA screening were performed later in pregnancy. Data on maternal characteristics and perinatal outcome were analyzed. RESULTS: Among 123 pregnant individuals with failed prenatal cfDNA screening, 68% were due to LFF and 32% to LQS. Obesity and autoimmune diseases were significantly overrepresented. A third prenatal cfDNA screening at 24 weeks was informative in 77.1% cases, with a higher success-rate in the LFF group (87.8%). Maternal autoimmune screening revealed unknown triple positivity for antiphospholipid antibodies in 2.4%. Abnormal perinatal outcome was registered in 69.9% of patients, with higher rates of adverse perinatal outcome in the LFF group. CONCLUSION: Persistent uninterpretable prenatal cfDNA screening indicates a higher risk for adverse perinatal outcomes, especially in cases with LFF. Maternal autoimmune screening should be considered to identify high-risk pregnancies. A third prenatal cfDNA screening later in pregnancy can help stratify truly high-risk pregnancies and allows patients with initially uninterpretable results to make an informed decision about diagnostic testing.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Lannoo L, Van Den Bogaert K, Belmans A, et al. Persistent Uninterpretable or Failed Prenatal Cell-Free DNA Screening Indicates a High-Risk Pregnancy and is Associated With Biological Factors Interfering With cfDNA-Analysis: A Prospective Cohort Study. Prenat Diagn. 2025. PMID: 40114366. doi:10.1002/pd.6778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。